AlphaMol Science Ltd

GPCR Drug Discovery Innovator.

Founded 2020 3 employees Series A Biopharma, Biotechnology +1

AlphaMol Science Ltd is a GPCR Drug Discovery Innovator that leverages computational methods and cutting-edge biotechnology to accelerate pre-clinical GPCR drug discovery. The company has achieved remarkable milestones by inventing three first-in-class PCC within 3-9 months, a process that typically takes 5-7 years using traditional methods. G protein-coupled receptors (GPCRs) are pivotal drug targets, with approximately 40% of marketed drugs targeting GPCRs. AlphaMol has established a dedicated GPCR-purposed platform for drug discovery, showcasing its capabilities by outperforming Google's AlphaFold2 in the GPCR-DOCK 2021 global contest and securing the best outstanding award in the NVIDIA Inception contest for startups in 2022. The company's co-founders, Prof. Shuguang Yuan and Prof. Horst Vogel, have been recognized among the "top 2%" scientists globally. The Series A investment at 24 August 2023 was led by Shanghai Healthcare Capital, Huaqiang Capital, and New Value Capital, emphasizing the industry's recognition and support for AlphaMol's groundbreaking approach to GPCR drug discovery.

Funding Stage	Amount	Investors	Lead Investors	Date
Series A	Undisclosed	3	Shanghai Healthcare Capital, Huaqiang Capital +1	24 Aug 2023
Angel Round	Undisclosed	2	New Value Capital, Shenzhen Hi-tech Investment Luohu Fund	01 May 2021
Seed Round	Undisclosed	-		01 Jul 2020

Funding Stage

Amount

Investors

Lead Investors

Date

Series A

Undisclosed

Shanghai Healthcare Capital, Huaqiang Capital +1

24 Aug 2023

Angel Round

Undisclosed

New Value Capital, Shenzhen Hi-tech Investment Luohu Fund

01 May 2021

Seed Round

Undisclosed

01 Jul 2020

FAQ About AlphaMol Science Ltd

GPCR Drug Discovery Innovator.

AlphaMol Science Ltd was founded in 2020.

AlphaMol Science Ltd operates in Biopharma, Biotechnology and Pharmaceutical. Its work centres on GPCR drug discovery, pharmaceuticals, pre-clinical drug discovery and computational methods.

AlphaMol Science Ltd has approximately 3 employees.

AlphaMol Science Ltd has completed 3 funding rounds. The latest funding stage is Series A.

Top alternatives and competitors to AlphaMol Science Ltd include Septerna, Cullgen Inc., Jupiter Neurosciences, Inc., vTv Therapeutics, ENDECE. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.

AlphaMol Science Ltd and Septerna are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

General Information

Discover More

About AlphaMol Science Ltd

Funding Rounds & Investors (3)

AlphaMol Science Ltd Alternatives & Competitors

FAQ About AlphaMol Science Ltd